The words and actions of US President Donald Trump are rocking the pharmaceutical industry. On May 5, he said he…
BUSINESS
AbbVie Japan Eyes Sales of 200 Billion Yen in 5 Years, Rinvoq and Skyrizi as Drivers
AbbVie is set to lift its Japan revenue to 200 billion yen within the next five years as it expects its immunology stars Rinvoq (upadacitinib) and Skyrizi (risankizumab) to continue driving its business. Along with this goal, it is also…
To read the full story
Related Article
- AbbVie Aims to Double Japan Sales to 200 Billion Yen by 2030: Local Chief
May 31, 2023
- AbbVie’s Japan Sales Sag 13% in 2021 as Off-Year Price Cuts, Synagis Return Weigh
May 19, 2022
- AbbVie Looks to Continue Double-Digit Annual Growth in New 5-Year Biz Plan
May 21, 2021
- Maviret Shrivels, but AbbVie Japan in “Growth Mode” with Oncology, Immunology Drivers: Chief
July 3, 2020
BUSINESS
- Japan Pharma Market Grows 1% to Record 11.4 Trillion Yen in FY2024: IQVIA
May 23, 2025
- Tecentriq-Avastin Yields Positive Data on HCC: China/Japan PIII
May 23, 2025
- Meiji, Sandoz Tie-Up to Secure Stable Supply of Antibiotic Intermediates
May 23, 2025
- Camzyos, Tremfya, Tivdak, and More Now Available in Japan
May 22, 2025
- Alloy Japan Now Up and Running to Deliver iCAR-T for Cancer Therapy Development
May 22, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…